Gαopotentiates estrogen receptor α activity via the ERK signaling pathway

Journal of Endocrinology

Volumn 214, Issue 1, 2012, Pages 45-54

  Bratton, Melyssa R ^a   WAntoon, James ^a   Duong, Bich N ^a   Frigo, Daniel E ^c   Tilghman, Syreeta ^a   Collins Burow, Bridgette M ^a   Elliott, Steven ^a   Tang, Yan ^a   Melnik, Lilia I ^a   Lai, Ling ^a   Alam, Jawed ^b   Beckman, Barbara S ^a   Hill, Steven M ^a   Rowan, Brian G ^a   McLachlan, John A ^a   Burow, Matthew E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECEPTOR SUBUNIT; TAMOXIFEN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; CELL STRAIN HEK293; CELL STRAIN MCF 7; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE; TRANSFECTION;

EID: 84864311891     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0097     Document Type: Article

References (78)

1. Aronica SM & Katzenellenbogen BS 1993 Stimulation of estrogen receptormediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 7, 743-752
2. Ballif BA & Blenis J 2001 Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth & Differentiation 12, 397-408.
3. Bartucci M, Morelli C, Mauro L, Ando S & Surmacz E 2001 Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Research 61 6747-6754.
4. Brazil DP, Park J & Hemmings BA 2002 PKB binding proteins. Getting in on the Akt. Cell 111 293-303
5. Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA & Beckman BS 1999 Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis 20 2057-2061
6. Cakir Y, Plummer HK III, Tithof PK & Schuller HM 2002 Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. International Journal of Oncology 21 153-157.
7. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824
8. Cantley LC 2002 The phosphoinositide 3-kinase pathway. Science 296 1655-1657
9. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM & Ali S 2000 Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Molecular Cell 6 127-137.
10. Cheskis BJ 2004 Regulation of cell signalling cascades by steroid hormones. Journal of Cellular Biochemistry 93 20-27
11. Cotta-Grand N, Rovere C, Guyon A, Cervantes A, Brau F & Nahon JL 2009 Melanin-concentrating hormone induces neurite outgrowth in human neuroblastoma SH-SY5Y cells through p53 and MAPKinase signaling pathways. Peptides 30 2014-2024
12. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF & Korach KS 1996 Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. PNAS 93 12626-12630
13. Diverse-Pierluissi M, Remmers AE, Neubig RR & Dunlap K 1997 Novel form of crosstalk between G protein and tyrosine kinase pathways. PNAS 94 5417-5421
14. Downes GB & Gautam N 1999 The G protein subunit gene families. Genomics 62 544-552
15. D'Souza DN, Zhang Y, Damjanoska KJ, Carrasco GA, Sullivan NR, Garcia F, Battaglia G, Doncarlos LL, Muma NA & Van de Kar LD 2004 Estrogen reduces serotonin-1A receptor-mediated oxytocin release and Galpha(i/o/z) proteins in the hypothalamus of ovariectomized rats. Neuroendocrinology 80 31-41
16. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH & Sussenbach JS 1997 Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. Journal of Biological Chemistry 272 31163-31171
17. Dunn SE, Torres JV, Oh JS, Cykert DM & Barrett JC 2001 Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Research 61 1367-1374.
18. Frigo DE, Burow ME, Mitchell KA, Chiang TC & McLachlan JA 2002 DDT and its metabolites alter gene expression in human uterine cell lines through estrogen receptor-independent mechanisms. Environmental Health Perspectives 110 1239-1245
19. Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME & McLachlan JA 2004 Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 25 249-261
20. Garcia-Marcos M, Ghosh P & Farquhar MG 2011 Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 30 2691-2696
21. Girgert R, Bartsch C, Hill SM, Kreienberg R & Hanf V 2003 Tracking the elusive antiestrogenic effect of melatonin: a new methodological approach. Neuro Endocrinology Letters 24 440-444.
22. Goel R, Phillips-Mason PJ, Gardner A, Raben DM & Baldassare JJ 2004 Alpha-thrombin-mediated phosphatidylinositol 3-kinase activation through release of Gbetagamma dimers from Galphaq and Galphai2. Journal of Biological Chemistry 279 6701-6710
23. He JC, Neves SR, Jordan JD & Iyengar R 2006 Role of the Go/i signaling network in the regulation of neurite outgrowth. Canadian Journal of Physiology and Pharmacology 84 687-694
24. Heasley L, Storey B, Fanger G, Butterfield L, Zamarripa J, Blumberg D & Maue R 1996 GTPase-deficient G alpha 16 and G alpha q induce PC12 cell differentiation and persistent activation of cJun NH2-terminal kinases. Molecular and Cellular Biology 16 648-656.
25. Hurst JH & Hooks SB 2009 Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochemical Pharmacology 78 1289-1297
26. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA & Korach KS 1992 Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. PNAS 89 4658-4662
27. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS & McLachlan JA 1993 Peptide growth factors elicit estrogen receptordependent transcriptional activation of an estrogen-responsive element. Molecular Endocrinology 7 992-998
28. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA & Korach KS 1996 Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137 1735-1744
29. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J et al. 2010 Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466 869-873
30. Kato S 2001 Estrogen receptor-mediated cross-talk with growth factor signaling pathways. Breast Cancer 8 3-9
31. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H et al. 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494
32. Kaur K, Parra S, Chen R, Charbeneau RA, Wade SM, Jay PY & Neubig RR 2012 Galpha(i2) signaling: friend or foe in cardiac injury and heart failure? Naunyn-Schmiedeberg's Archives of Pharmacology 385 443-453
33. Kenney NJ & Dickson RB 1996 Growth factor and sex steroid interactions in breast cancer. Journal of Mammary Gland Biology and Neoplasia 1 189-198
34. Kimple AJ, Bosch DE, Giguere PM & Siderovski DP 2011 Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacological Reviews 63 728-749
35. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP & Korach KS 2002 Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. Journal of Biological Chemistry 277 8531-8537
36. Kroll SD, Omri G, Landau EM & Iyengar R 1991 Activated alpha subunit of Go protein induces oocyte maturation. PNAS 88 5182-5186
37. Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M et al. 2009 Mutational profile of GNAQQ209 in human tumors. PLoS ONE 4 e6833
38. Lania A, Mantovani G & Spada A 2001 G protein mutations in endocrine diseases. European Journal of Endocrinology 145 543-559
39. Lee AV, Cui X & Oesterreich S 2001 Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clinical Cancer Research 7 4429s-4435s (discussion 4411s-4412s).
40. Le Goff P, Montano MM, Schodin DJ & Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. Journal of Biological Chemistry 269 4458-4466
41. Levin ER 2005 Integration of the extranuclear and nuclear actions of estrogen. Molecular Endocrinology 19 1951-1959
42. Lin C, Ear J, Pavlova Y, Mittal Y, Kufareva I, Ghassemian M, Abagyan R, Garcia-Marcos M & Ghosh P 2011 Tyrosine phosphorylation of the Galpha-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration. Science Signaling 4 ra64
43. Liu JC, Baker RE, Sun C, Sundmark VC & Elsholtz HP 2002 Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. Journal of Biological Chemistry 277 35819-35825
44. Liu J, Youn H, Yang J, Du N, Liu J, Liu H & Li B 2011 G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. Prostate 71 1276-1286.
45. Livingstone JD, Lerant A & Freeman ME 1998 Ovarian steroids modulate responsiveness to dopamine and expression of G-proteins in lactotropes. Neuroendocrinology 68 172-179
46. Maestroni GJ 1999 Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. Advances in Experimental Medicine and Biology 467 217-226.
47. Marinissen MJ, Servitja JM, Offermanns S, Simon MI & Gutkind JS 2003 Thrombin protease-activated receptor-1 signals through Gq- and G13-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. Journal of Biological Chemistry 278 46814-46825
48. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE & Stoica A 2000 A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulinlike growth factor I. Endocrinology 141 4503-4511
49. Musgrove EA & Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nature Reviews Cancer 9 631-643
50. Nava VE, Hobson JP, Murthy S, Milstien S & Spiegel S 2002 Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Experimental Cell Research 281 115-127
51. Nguyen QD, Faivre S, Bruyneel E, Rivat C, Seto M, Endo T, Mareel M, Emami S & Gespach C 2002 RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. FASEB Journal 16 565-576
52. Ogawa T, Forero M, Burgon PG, Kuroski de Bold ML, Georgalis T & de Bold AJ 2009 Role of potassium channels in stretch-promoted atrial natriuretic factor secretion. Journal of the American Society of Hypertension 3 9-18
53. Power RF, Mani SK, Codina J, Conneely OM & O'Malley BW 1991 Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254 1636-1639
54. Prevost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A et al. 2006 Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Research 66 9227-9234
55. Radeff-Huang J, Seasholtz TM, Matteo RG & Brown JH 2004 G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. Journal of Cellular Biochemistry 92 949-966
56. Radhika V & Dhanasekaran N 2001 Transforming G proteins. Oncogene 20 1607-1614
57. Ram PT, Kiefer T, Silverman M, Song Y, Brown GM & Hill SM 1998 Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors. Molecular and Cellular Endocrinology 141 53-64
58. Ram PT, Horvath CM & Iyengar R 2000a Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Galphao protein. Science 287 142-144
59. Ram PT, Yuan L, Dai J, Kiefer T, Klotz DM, Spriggs LL & Hill SM 2000b Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. Journal of Pineal Research 28 210-218
60. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS & Ramos S 1999 Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB Journal 13 857-868.
61. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P & Levin ER 2003 Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Molecular and Cellular Biology 23 1633-1646
62. Re G, Badino P, Dacasto M, Di Carlo F & Girardi C 1993 Regulation of uterine estrogen receptors (ER) by beta-adrenergic stimulation in immature rats. Journal of Veterinary Pharmacology and Therapeutics 16 328-334
63. del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS & Ramos S 2004 Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. Journal of Biological Chemistry 279 38294-38302
64. Rockman HA, Koch WJ & Lefkowitz RJ 2002 Seven-transmembranespanning receptors and heart function. Nature 415 206-212
65. Sanchez-Barcelo EJ, Cos S, Fernandez R & Mediavilla MD 2003 Melatonin and mammary cancer: a short review. Endocrine-Related Cancer 10 153-159
66. Schulte G & Fredholm BB 2003 The G(s)-coupled adenosine A(2B) receptor recruits divergent pathways to regulate ERK1/2 and p38. Experimental Cell Research 290 168-176
67. Sheeler CQ, Singleton DW & Khan SA 2003 Mutation of serines 104, 106, and 118 inhibits dimerization of the human estrogen receptor in yeast. Endocrine Research 29 237-255
68. Shupnik MA 2004 Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23 7979-7989
69. Simoncini T, Scorticati C, Mannella P, Fadiel A, Giretti MS, Fu XD, Baldacci C, Garibaldi S, Caruso A, Fornari L et al. 2006 Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Molecular Endocrinology 20 1756-1771
70. Smith CL, Conneely OM & O'Malley BW 1993 Modulation of the ligandindependent activation of the human estrogen receptor by hormone and antihormone. PNAS 90 6120-6124
71. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA & Xia P 2003 Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Molecular Endocrinology 17 2002-2012
72. Vassart G & Costagliola S 2011 G protein-coupled receptors: mutations and endocrine diseases. Nature Reviews Endocrinology 7 362-372
73. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM & Shaul PW 2001 Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). Journal of Biological Chemistry 276 27071-27076
74. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y & Iwase H 2008 Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocrine-Related Cancer 15 755-763
75. Yamauchi J, Nagao M, Kaziro Y & Itoh H 1997 Activation of p38 mitogenactivated protein kinase by signaling through G protein-coupled receptors. Involvement of Gbetagamma and Galphaq/11 subunits. Journal of Biological Chemistry 272 27771-27777
76. Yuan L, Collins AR, Dai J, Dubocovich ML & Hill SM 2002 MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Molecular and Cellular Endocrinology 192 147-156
77. Zhao A, Ohara-Imaizumi M, Brissova M, Benninger RK, Xu Y, Hao Y, Abramowitz J, Boulay G, Powers AC, Piston D et al. 2010 Gao represses insulin secretion by reducing vesicular docking in pancreatic beta-cells. Diabetes 59 2522-2529
78. Zoubir M, Mathieu MC, Mazouni C, Liedtke C, Corley L, Geha S, Bouaziz J, Spielmann M, Drusche F, Symmans WF et al. 2008 Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Annals of Oncology 19 1402-1406